These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25659328)

  • 21. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
    Dranitsaris G; Amir E; Dorward K
    Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biosimilar medicines. Scientific and legal disputes].
    Dorantes Calderón B; Montes Escalante IM
    Farm Hosp; 2010 Mar; 34 Suppl 1():29-44. PubMed ID: 20920856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.
    Sharma A; Kumar N; Kuppermann BD; Bandello F; Loewenstein A
    Br J Ophthalmol; 2020 Jan; 104(1):2-7. PubMed ID: 31315829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of the Medicines Control Council backlog and fast-track review system on access to innovative and new generic and biosimilar medicines of public health importance in South Africa.
    Leng HM; Pollock AM; Sanders D
    S Afr Med J; 2016 Mar; 106(4):43-6. PubMed ID: 27032846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the bioequivalence of biosimilars The Retacrit case.
    Schellekens H
    Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
    Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
    Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Update of the Brazilian Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products.
    Soares KC; Santos GM; Gelfuso GM; Gratieri T
    AAPS J; 2015 Nov; 17(6):1517-8. PubMed ID: 26122498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
    Szeto KJ; Wolanski M
    Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
    Warren JB
    Br J Clin Pharmacol; 2013 Jan; 75(1):7-14. PubMed ID: 22574725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rheological and molecular weight comparisons of approved hyaluronic acid products - preliminary standards for establishing class III medical device equivalence.
    Braithwaite GJ; Daley MJ; Toledo-Velasquez D
    J Biomater Sci Polym Ed; 2016; 27(3):235-46. PubMed ID: 26569146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of animal studies to evaluate the similarity of biosimilars to reference products.
    van Meer PJ; Ebbers HC; Kooijman M; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    Drug Discov Today; 2015 Apr; 20(4):483-90. PubMed ID: 25463036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.
    Lunawat S; Bhat K
    Ther Innov Regul Sci; 2020 Sep; 54(5):991-1000. PubMed ID: 31960290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.